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A
utoimmune diseases afﬂ  ict a 
large segment of the population 
in Western countries. Many 
of them have been described, and 
rheumatoid arthritis, type I diabetes 
(also called insulin-dependent diabetes 
mellitus), multiple sclerosis, and 
systemic lupus erythematosus (SLE) are 
among the most common. Although 
tremendous progress has been made 
in disease management over the last 
decade, cures for these diseases have 
not yet been found. Consequently, a 
large research effort is sustained in this 
ﬁ  eld. In addition, autoimmunity has 
intrigued basic immunologists since 
the early realization that the ability to 
discriminate self from non-self was at 
the core of the immune system’s ability 
to protect an organism from pathogens 
while avoiding self-destruction. A 
failure of this mechanism results in 
autoimmune reactions that often lead 
to clinical disease. In spite of massive 
research efforts, the mechanisms by 
which autoimmune diseases develop 
are not clearly understood. Genetic 
predisposition as well as environmental 
triggers plays a role, but the identity of 
these factors has been largely elusive. 
The identiﬁ  cation of the most common 
genetic and environmental factors 
that set off autoimmunity may lead to 
a better understanding of the ensuing 
pathogenesis, and offers the best hope 
for improved therapies, and ultimately, 
cures.
So far, animal models have proved 
the best way to probe the mechanisms 
of disease in general, and autoimmune 
diseases in particular. In the past few 
decades, the mouse has become the 
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model of choice for experimental 
medicine, and the rat is following close 
behind. Starting in the early twentieth 
century at the Jackson Laboratory 
(Bar Harbor, Maine, United States), 
the production of inbred strains of 
mice and the systematic collection 
and characterization of naturally 
occurring mutants have created the 
building blocks on which much of the 
research using animal models is now 
based. Inbred strains are collections of 
genetically identical animals obtained 
through selective breeding. These 
strains have provided homogenous 
experimental groups, with inter-
individual variability reduced to 
environmental (and stochastic) factors. 
In addition, inbred strains have an 
assortment of distinct phenotypes that 
have then been exploited as models of 
human diseases. 
Since the 1980s, techniques have 
been developed to manipulate the 
mouse genome. Speciﬁ  c genes now 
can be routinely over-expressed as 
transgenes, or eliminated by gene 
targeting, which creates a “knockout” 
(Smithies 1993; Wassarman and 
DePamphilis 1993). This approach, 
known as reverse genetics, has shown 
itself to be a powerful tool with which 
to evaluate the role of individual 
genes in various biological processes. 
The use of genetically engineered 
mouse models will likely play a major 
role in deciphering the function of a 
multitude of new genes revealed in 
the recently completed sequence of 
the mouse genome (Mouse Genome 
Sequencing Consortium 2002). 
Interestingly, the percentage of 
mouse genes without any homolog 
currently detectable in the human 
genome (and vice versa) has been 
estimated to be less than 1%, a fact 
that strengthens the validity of mouse 
models of human diseases. However, 
one has to be careful in directly 
applying data obtained from animal 
models to human diseases. Most 
human autoimmune diseases show 
an extremely heterogeneous clinical 
presentation, which animal models 
present as simpliﬁ  ed versions. A 
mouse model, as in any reductionist 
approach, is both inconvenient, 
because it provides only a partial 
representation of the real biological 
complexity underlying the human 
disease, and advantageous, because it 
is a more tractable tool with which to 
probe mechanistic issues. In addition, 
a number of differences exist between 
the human and rodent immune systems 
(Mestas and Hughes 2004). Since 
immune dysfunctions are at the root of 
autoimmune diseases, such differences 
may limit extrapolations from animal 
models to autoimmune patients.
Nonetheless, animal models are 
at the core of autoimmune research, 
and a large body of literature reﬂ  ects 
the many advances brought by these 
models in terms of deciphering 
disease mechanisms. The relative 
lack of progress in certain human 
autoimmune diseases for which an 
animal model does not exist, such as 
neuropsychiatric lupus, corroborates 
the indispensable role played by animal 
models. Three basic types of animal 
models have been used in autoimmune 
research: spontaneous models, induced 
models, and genetically engineered 
models. The latter category has been 
further subdivided into transgenic and 
knockout strains (Table 1).
Spontaneous models were produced 
through fortuitous observations of 
clinical symptoms reminiscent of a 
given human autoimmune disease 
developing in a given mouse strain, or 
in crosses between mouse strains. This 
happened, for example, with the non-
obese diabetic (NOD) mouse, which 
developed type 1 diabetes, and the 
hybrid between the New Zealand Black 
(NZB) and the New Zealand White 
(NZW) mouse, (NZB × NZW)F1, which 
developed a lupus-like disease. 
Unfortunately, spontaneous models 
are not available for all human 
autoimmune diseases. Therefore, 
scientists have created induced models, 
often by exposing the animals to high 
doses of a suspected autoantigen 
at the same time as stimulating the 
immune system. Interestingly, marked 
differences exist between strains in 
their responses to these autoimmune 
inductions that reﬂ  ect genetic variation 
associated with susceptibility to 
autoimmune diseases. For this reason, 
induced models have been limited 
to a small number of strains. For 
example, experimental autoimmune 
encephalomyelitis has been widely 
used as a model of multiple sclerosis. 
In this model, spinal cord homogenate 
or a protein derivative such as myelin 
basic protein is injected with a mixture 
of potent immunostimulants, most 
commonly in mice from the SJL strain. 
Another example of an induced model 
is collagen-induced arthritis, which 
has been used to study rheumatoid 
arthritis. In this model, type II collagen, 
a joint component, is injected also with 
immunostimulants, most commonly 
into mice from the DBA/1 strain.
Finally, the ability to turn speciﬁ  c 
genes on or off, in speciﬁ  c cell types 
and/or at speciﬁ  c times, has created a 
plethora of mouse models limited only 
by the immunologist’s imagination. 
Genes suspected to play a role in the 
pathogenesis of various autoimmune 
diseases have been evaluated this 
way, and those studies have been very 
August 2004  |  Volume 2  |  Issue 8  |  e241
Table 1. Examples of Common Mouse Models of Autoimmune Diseases
Type of Mouse Model Mouse Model Human Disease
Spontaneous NOD Type 1 diabetes
Spontaneous (NZB × NZW)F1, MRL/lpr   SLE
Induced Experimental autoimmune 
encephalytis in SJL
 Multiple sclerosis
Induced Collagen-induced arthritis in 
DBA/1
 Rheumatoid arthritis
Transgenic Bcl-2 transgene SLE
Knockout Apcs−/− SLE
DOI: 10.1371/journal.pbio.0020241.t001PLoS Biology  |  www.plosbiology.org 1063
informative in mapping out functional 
pathways that are targeted in these 
diseases. However, these models 
have intrinsic problems that have 
become more apparent in the past 
few years, and require careful controls 
to avoid possible misinterpretation. 
These problems are a result of the 
fundamental way in which transgenic 
and knockout strains are produced. 
When a piece of DNA carrying 
the gene of interest is injected as a 
“transgene” into fertilized eggs, it 
integrates randomly into the genome, 
and in doing so, potentially modiﬁ  es 
the expression of the gene it integrates 
into. Since all genetic studies have 
recognized that a large number of 
genes are involved in autoimmune 
disease susceptibility, the potential 
for a transgene to hit one of those 
susceptibility genes is not negligible. 
This potentially confounding factor 
is usually controlled by producing 
and comparing several independent 
transgenic lines. 
More problematic is the 
interpretation of results obtained 
with knockout models. A gene is 
“knocked out” (KO) by homologous 
recombination of a disrupting piece 
of DNA within that gene. This genetic 
manipulation takes place in embryonic 
stem (ES) cells, which once mutated, 
are introduced into the inner cavity of 
a blastocyst (very early mouse embryo), 
creating chimeric embryos that are 
put back into female mice that carry 
the pregnancy to term. After multiple 
trials (and errors), ES cell lines from 
the 129 strain and blastocysts from 
the C57BL/6 (B6) strain have shown 
themselves to be superior in terms of 
efﬁ  ciency and reliability. Consequently, 
this strain combination is at the 
origin of the overwhelming majority 
of knockout strains. Although the 
chimeric mice are usually backcrossed 
to B6 to dilute the contribution of the 
129 genome, the knockout strains are 
always a mixture of the two genomes 
(Figure 1). Most importantly, a large 
region ﬂ  anking the KO gene remains 
of 129 origin, unless extreme measures 
are taken to select for recombination 
between tightly linked markers. 
There have been sporadic reports 
of phenotypes initially attributed 
to deﬁ  ciency in the expression of 
a given gene that disappeared with 
additional backcrosses to B6. The only 
possible interpretation was that these 
phenotypes were in fact due to 129 
alleles that were replaced by B6 alleles 
with further backcrossing. 
The production of autoantibodies and 
mild antibody-related renal pathology, 
highly relevant to autoimmune 
diseases, especially SLE, has been 
reported independently in four mouse 
models using the (129 × B6) genetic 
background (Obara et al. 1979; Botto et 
al 1998; Bickerstaff et al. 1999; Santiago-
Raber et al. 2001). It is generally 
accepted that genetic susceptibility to 
autoimmune diseases is conferred by 
multiple highly interactive genes that 
have small individual effects. In this 
context, the autoimmune phenotypes 
resulting from the combination of 
the 129 and B6 genomes may might 
therefore provide a primed background 
upon which the effects of deﬁ  ciency 
in the target gene can be ampliﬁ  ed. 
On the other hand, the autoimmune 
phenotype may be overwhelmingly 
contributed by the (129 × B6) genomic 
combination, with little if any effect of 
the deﬁ  ciency of the KO gene. 
In this issue of PLoS Biology, Marina 
Botto and her colleagues have tested 
this hypothesis by taking one of their 
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Figure 1. Breeding Strategy Usually Performed to Transfer a KO Allele from the 129 Genome to the 
C57BL/6 (B6) Genome
For clarity, only 4 of the 20 pairs of the mouse chromosomes are represented by black 
(B6) or red (129) bars. The KO allele is shown by a white box. Chimeric males are 
obtained from the integration of ES cells from the 129 strain that have been engineered 
to carry the KO allele to B6 blastocysts. These males are then bred to normal B6 females, 
resulting in an N1 progeny that is made up of 50% B6 and 50% 129 genome. N1 mice 
are subsequently “backcrossed” to B6, and their N2 progeny is selected for the presence 
of the KO allele. The contribution of 129 genome among the N2 progeny is normally 
distributed around a mean of 25%. This process can be repeated (shown here to N4), 
resulting in an average reduction of the 129 genome to one half of what it was in the 
previous generation. At any point in the process, homozygosity for the KO allele, 
which is necessary to prevent expression of that gene, can be obtained by intercrossing 
heterozygous mice, shown here at N4.PLoS Biology  |  www.plosbiology.org 1064
knockout models for SLE, the serum 
amyloid P component deﬁ  cient mouse 
(Apcs−⁄−) (Bygrave et al. 2004). This 
group has published that Apcs−⁄− mice 
on a (129 × B6) genetic background 
develop a lupus-like disease, even 
after repeated backcrosses to B6 
(Bickerstaff et al. 1999). Serum 
amyloid P component binds to debris 
generated from dying cells. Efﬁ  cient 
removal of this debris has been shown 
to be critical to the prevention of 
the production of autoantibodies 
against intracellular material. Apcs was 
therefore an interesting candidate 
gene to evaluate. Apcs, however, is 
located in a region near the tip of 
mouse Chromosome 1 that is rich in 
SLE susceptibility loci and in genes 
that have been directly associated 
with SLE in humans (Wakeland et 
al. 1999). As mentioned above, the 
Apcs−⁄− mouse, although on a mostly 
B6 genomic background, has its entire 
Apcs ﬂ  anking region replaced with 
129 alleles. In a critical experiment, 
Botto and colleagues compared 
the autoimmune phenotypes of 
Apcs−⁄− mice to congenic mice (i.e., 
genetically identical, except for 
the gene of interest), carrying the 
same 129 region on Chromosome 1, 
but expressing Apcs. Amazingly, no 
difference was found between the two 
strains regarding the production of 
autoantibodies, clearly eliminating 
Apcs deﬁ  ciency as a mechanism for this 
autoimmune process. Apcs deﬁ  ciency 
was however associated with markedly 
increased renal damage, suggesting 
that this gene may be involved in 
preventing pathological consequences 
of autoantibody production.
It has been reported anecdotally that 
the most common outcome of a genetic 
knockout is a lupus-like disease. Botto 
and her colleagues may have identiﬁ  ed 
the reason behind this somewhat 
surprising observation as a spurious 
consequence of the gene-targeting 
process. Gene targeting has been an 
invaluable tool in understanding the 
mechanisms of immunological diseases, 
and has still a very important role to 
play with increasingly sophisticated 
techniques of selective targeting. 
The immediate consequence of this 
work should be an increased scrutiny 
for appropriate controls, which may 
include congenic mice carrying 
the same 129 ﬂ  anking region, but 
expressing the targeted gene (Figure 2).
The past few years have shown that 
genetic susceptibility to autoimmune 
diseases involves a large number 
of genes with small individual 
contributions. In spite of this great 
complexity, advances have been made, 
and a small but growing number 
of susceptibility genes have been 
identiﬁ  ed (Morahan and Morel 2002). 
A common trait shared by successful 
studies has been the use of mouse 
models, either directly or indirectly. As 
the pace of genetic analysis increases 
in autoimmune diseases, and powerful 
tools have been created to navigate 
between the mouse and human 
genomes, the use of mouse models 
has been reafﬁ  rmed at multiple levels. 
Mouse models are used to discover 
new susceptibility genes that can then 
be assessed in patient populations, as 
well as to validate genes that have been 
directly identiﬁ  ed in human genetic 
studies. Mouse models are also used 
to perform detailed functional and 
physiological analyses that cannot be 
conducted in humans. Finally, mouse 
models have been invaluable to screen 
disease-speciﬁ  c therapeutic agents.
Using mouse models has its pitfalls; 
many differences, both obvious 
and subtle, exist between mice and 
humans. Those differences are, 
however, outweighed by the power 
of the experimental system offered 
by the mouse. What the new study of 
Botto and colleagues reminds us is that 
the appropriate control is still crucial 
to meaningful data interpretation. 
Keeping that in mind, one can predict 
that many of the keys to human 
autoimmune diseases are still in the 
mouse room.  
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Figure 2. Congenic Strains (Left and Right) of a Lupus-Prone Mouse (Middle). Image courtesy of 
Jessica Merritto.